Abvc Biopharma (ABVC) Interest Coverage Ratio (2010 - 2026)
Abvc Biopharma's (ABVC) quarterly Interest Coverage Ratio came in at 18.42 in Q2 2026, down 3.86% on a YoY basis from 19.16 in Q2 2025, and up 42.16% quarter-over-quarter from 31.85 in Q1 2026.
Powered by 
Analysis
Abvc Biopharma (ABVC) Interest Coverage Ratio (2010 - 2026) Analysis & Trends
Abvc Biopharma (ABVC) has reported Interest Coverage Ratio for 14 consecutive years, with 18.42 the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Interest Coverage Ratio fell 3.86% year-over-year to 18.42; the trailing twelve-month figure through Jun 2026 stood at 41.98 (down 729.61% YoY), and the FY2025 full-year result was 17.2, down 201.82% from the prior year.
- Interest Coverage Ratio rose to 18.42 in Q2 2026 per ABVC's latest filing, from 31.85 in the prior quarter.
- Across five years, Interest Coverage Ratio topped out at 6.7 in Q4 2023 and bottomed at 341.44 in Q1 2022.
- Historically, Interest Coverage Ratio has averaged 44.84 across 5 years, with a median of 18.77 in 2026.
- The sharpest annual moves came in 2023 and 2025: Interest Coverage Ratio soared 128.76% in 2023, then tumbled 4526.38% in 2025.
- Over 5 years, Interest Coverage Ratio stood at 23.3 in 2022, then jumped by 128.76% to 6.7 in 2023, then sank by 148.51% to 3.25 in 2024, then sank by 1977.84% to 67.55 in 2025, then soared by 72.73% to 18.42 in 2026.
- According to Business Quant data, Interest Coverage Ratio over the past three periods registered 18.42, 31.85, and 67.55 for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 5.22 |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | -42.08 |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 117.59 |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | 493.00 |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 2.82 |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | - |
| 10 | Abvc Biopharma | 25.56 Mn | 25.56 Mn | - | -18.42 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -18.42 |
| Mar 31, 2026 | -31.85 |
| Dec 31, 2025 | -67.55 |
| Sep 30, 2025 | -63.45 |
| Jun 30, 2025 | -17.73 |
| Mar 31, 2025 | -3.11 |
| Dec 31, 2024 | -3.25 |
| Sep 30, 2024 | -1.37 |
| Jun 30, 2024 | -4.15 |
| Mar 31, 2024 | -15.62 |
| Dec 31, 2023 | 6.70 |
| Sep 30, 2023 | -1.77 |
| Jun 30, 2023 | -19.12 |
| Mar 31, 2023 | -33.64 |
| Dec 31, 2022 | -23.30 |
| Sep 30, 2022 | -29.37 |
| Jun 30, 2022 | -138.69 |
| Mar 31, 2022 | -341.44 |
| Dec 31, 2021 | 264.59 |
| Sep 30, 2021 | -50.95 |